3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroendocrine Tumors
5
Gastro-enteropancreatic neuroendocrine tumor
2
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
Specimen Handling
4
lutetium Lu 177 dotatate
3
gallium Ga 68 dotatate
3
Magnetic Resonance Spectroscopy
3
olaparib
2
cabozantinib
2
belzutifan
2
Temozolomide
2
Nivolumab
2
Fluorodeoxyglucose F18
2
Biopsy
2
talazoparib
1
spartalizumab
1
pembrolizumab
1
lanreotide
1
guadecitabine
1
fludarabine phosphate
1
copper dotatate CU-64
1
atezolizumab
1
Phenoxybenzamine
1
ONC206
1
Lutetium-177
1
Lutetium
1
Ipilimumab
1
Interleukin-13
1
Genetic Testing
1
Everolimus
1
Cyclophosphamide
1
Contrast Media
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Paraganglioma
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
1 year
×
Clear all
No trials found.